Dubai Healthcare City Authority (DHCA) has revealed an ambitious AED 1.3 billion development plan for Phase 1 of Dubai Healthcare City (DHCC), reaffirming its position as one of the region's most dynamic hubs for healthcare innovation, sustainability, and global investment.
The Government of Dubai Media Office announced the plan on 12 October 2025, detailing the first wave of projects that include a LEED Platinum-certified office building, a purpose-built medical complex, and upgraded infrastructure designed to elevate DHCC's appeal to international investors and healthcare providers.
Issam Galadari, Chief Executive Officer of Dubai Healthcare City Authority, said: "Our upcoming development plan, starting with these flagship projects, reflects our commitment to contribute to shaping the future of healthcare infrastructure in Dubai. By creating an ecosystem that attracts investments, including FDI, and fosters innovation, while integrating sustainability with world-class design, we are aligning with the Dubai Economic Agenda, D33, and the UAE Net Zero Strategy 2050. Through the ongoing development, we will continue to cement DHCC's position as the enabling healthcare and wellness destination for the region and beyond."
The new LEED Platinum-certified office tower, designed by award-winning firm P&T Architects and Engineers Ltd, will become the first of its kind within DHCC. Covering 13,000 square metres across three basement levels and nine storeys, it will feature flexible office configurations and retail units at ground level. The building aims to set a benchmark for sustainable design and environmental excellence, meeting the highest international standards.
Complementing this is a new medical complex, conceptualised by Dubai-based Design and Architecture Bureau (DAR). Occupying 5,800 square metres, the complex will consist of two basement levels and five floors, providing adaptable space for surgery suites, laboratories, diagnostic centres, outpatient clinics, and healthcare offices. Its shell-and-core design, efficient floor layouts, and integrated smart parking will ensure long-term operational flexibility for tenants and healthcare operators.
To support the wider DHCC community, the Authority will also deliver modern, multi-storey car parks fitted with electric vehicle charging facilities, Salik-enabled smart parking, and universal accessibility features, aligning with Dubai's broader urban mobility vision.
Allae Almanini, Chief Operating Officer at Dubai Healthcare City Authority, added: "Our priority is to deliver infrastructure that enables growth and creates confidence for healthcare providers and investors. These projects will enhance accessibility, sustainability, and efficiency across the community, ensuring that DHCC remains the most attractive healthcare investment destination in the region."
Construction work is scheduled to commence in December 2025, with the full completion of all major components expected by November 2027.
source:newsreleases.co.uk
Relay Therapeutics wins FDA breakthrough status for zovegalisib in breast cancer treatment
DATROWAY receives US priority review for first-line metastatic triple negative breast cancer
Valneva and Instituto Butantan launch pilot chikungunya vaccination campaign in Brazil
Lupin launches Dasatinib tablets in US market
WuXi Biologics enters into licence and research service agreement with Vertex Pharmaceuticals
Natera submits Signatera CDx PMA to FDA for bladder cancer use
Pharming receives FDA complete response letter for paediatric Joenja application
Astrazeneca Imfinzi perioperative regimen gains positive EU CHMP opinion in early gastric cancer
I Peace generates human iPS cells from NKT cells and offers them for research use
Trace Biosciences' IND application for nerve-specific imaging agent approved by FDA
Frontage expands early phase clinical research capabilities across US and China
AstraZeneca agrees obesity and type 2 diabetes collaboration with CSPC
Ascletis Pharma Inc reports topline results from Phase III open-label study of denifanstat
Innovative Molecules GmbH completes Phase 1 clinical development programme for adibelivir
MicuRx Pharmaceuticals' IND application for MRX-5 cleared by FDA